Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
|Articles|December 10, 2021
Daily Medication Pearl: Glipizide (Glucotrol)
Author(s)Saro Arakelians, PharmD
Glipizide stimulates beta cells to produce more insulin in the body.
Advertisement
Medication Pearl of the Day: Glipizide (Glucotrol)
Indication: Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class.
Insight:
- Dosing: The recommended starting dose is 5 mg, given before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg.
- Dosage forms: 5 mg and 10 mg
- Adverse events: Includes gastrointestinal disturbances, erythema, low blood sugars, leukopenia, hyponatremia, dizziness, and drowsiness.
- Mechanism of action: Glipizide stimulates the beta cells of the pancreas to produce more insulin in the body.
- Manufacturer: Pfizer
Sources:
Advertisement
Related to this article
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
5